Scinai Immunotherapeutics Ltd. (TLV:BVXV)
Israel · Delayed Price · Currency is ILS · Price in ILA 49.30
-1.00 (-1.99%)
At close: Jan 18, 2018
Scinai Immunotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.65 | 1.66 | 1.96 | 4.87 | 14.08 | 17.37 |
Cash & Short-Term Investments | 2.65 | 1.66 | 1.96 | 4.87 | 14.08 | 17.37 |
Cash Growth | 168.35% | -15.43% | -59.67% | -65.40% | -18.99% | 492.87% |
Accounts Receivable | 0.07 | 0.07 | 0.08 | - | - | - |
Other Receivables | - | 0.1 | 0.13 | 0.37 | 0.11 | 0.1 |
Receivables | 0.07 | 0.17 | 0.22 | 0.37 | 0.11 | 0.1 |
Prepaid Expenses | 0.56 | 0.08 | 0.08 | 0.07 | 0.05 | 0.23 |
Restricted Cash | 0.2 | 0.15 | 0.13 | 0.14 | 0.14 | 0.14 |
Total Current Assets | 3.49 | 2.05 | 2.39 | 5.45 | 14.37 | 17.84 |
Property, Plant & Equipment | 13.69 | 9.57 | 11.06 | 12.03 | 12.7 | 14.19 |
Total Assets | 17.18 | 11.63 | 13.45 | 17.47 | 27.07 | 32.04 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.84 | 0.41 | 0.38 | 0.54 | 0.72 | 1 |
Accrued Expenses | - | 0.76 | 0.78 | 0.85 | 1.24 | 1.07 |
Current Portion of Leases | 0.37 | 0.33 | 0.42 | 0.4 | 0.38 | 0.38 |
Current Unearned Revenue | - | 0.09 | 0.23 | - | - | - |
Total Current Liabilities | 2.23 | 1.59 | 1.81 | 1.78 | 2.34 | 2.44 |
Long-Term Debt | 0.29 | 0.29 | 0.26 | 19.37 | 20.08 | 27.16 |
Long-Term Leases | 2.93 | 1.64 | 1.4 | 0.8 | 1.08 | 1.45 |
Other Long-Term Liabilities | - | - | 0 | 0.1 | 5.33 | - |
Total Liabilities | 5.44 | 3.52 | 3.47 | 22.04 | 28.83 | 31.05 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 132.52 | 130.06 | 123.63 | 119.51 | 116.08 | 113.08 |
Retained Earnings | -124.27 | -125.85 | -117.54 | -122.34 | -115.84 | -110.04 |
Comprehensive Income & Other | -2.14 | -1.74 | -1.74 | -1.74 | -2.01 | -2.06 |
Total Common Equity | 6.11 | 2.48 | 4.35 | -4.57 | -1.76 | 0.98 |
Shareholders' Equity | 11.73 | 8.1 | 9.98 | -4.57 | -1.76 | 0.98 |
Total Liabilities & Equity | 17.18 | 11.63 | 13.45 | 17.47 | 27.07 | 32.04 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.58 | 2.27 | 2.09 | 20.56 | 21.54 | 28.99 |
Net Cash (Debt) | -0.93 | -0.61 | -0.12 | -15.69 | -7.47 | -11.61 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.74 | -2.60 | -1.51 | -401.65 | -396.09 | -822.66 |
Filing Date Shares Outstanding | 0.57 | 0.35 | 0.09 | 0.05 | 0.03 | 0.02 |
Total Common Shares Outstanding | 0.57 | 0.35 | 0.09 | 0.05 | 0.03 | 0.02 |
Working Capital | 1.26 | 0.47 | 0.59 | 3.67 | 12.03 | 15.4 |
Book Value Per Share | 10.71 | 7.14 | 51.00 | -98.41 | -53.59 | 52.16 |
Tangible Book Value | 6.11 | 2.48 | 4.35 | -4.57 | -1.76 | 0.98 |
Tangible Book Value Per Share | 10.71 | 7.14 | 51.00 | -98.41 | -53.59 | 52.16 |
Machinery | - | 9.95 | 9.92 | 2.46 | 1.92 | 1.23 |
Construction In Progress | - | - | - | 7.45 | 7.83 | 8.86 |
Leasehold Improvements | - | 3.72 | 3.72 | 3.72 | 3.92 | 4.43 |